This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oxigene Surprises With Positive Ovarian Cancer Study Success

SOUTH SAN FRANCISCO (TheStreet) -- Oxigene's (OXGN) experimental cancer drug Zybrestat, when used in combination with Roche's (RHHBY) Avastin, delayed the re-growth of ovarian cancer, according to results from a phase II study released Tuesday night.

The news was a surprise and sent shares of tiny Oxigene soaring 134% to $5.65 in Tuesday's after-hours trading session. Oxigene has a tiny float and a very large retail shareholder ownership base, so Wednesday's volatility should be fun to watch. 

Oxigene has been developing Zybrestat for various cancers without much success for years, but the company might have finally found a winning lottery ticket. The company was flinty with details from the ovarian cancer study so there's still a lot of data we don't have but need to know before understanding how Zybrestat may fit into the ovarian cancer treatment picture, if at all.

But from nothing there is now hope. To give you a sense of just how lost in the wilderness Oxigene had become, here's a five-year chart:


OXGN Chart
OXGN
data by YCharts

Yes, you're reading this correctly. Account for all the reverse stock splits and Oxigene was a $500-plus stock in 2009.

The phase II study, conducted by the non-profit Gynecologic Oncology Group, not Oxigene, enrolled 107 women with platinum-sensitive and resistant, recurrent ovarian cancer. The patients were randomized to receive either Roche's Avastin alone, or a combination of Zybrestat and Avastin. 

On the study's primary endpoint, the combination of Zybrestat and Avastin reduced the risk of tumor regrowth or death (progression-free survival) by 32% compared to Avastin alone. The result was statistically significant. Oxigene did not report the median progression-free survival for the patients in the study. 

Response rate (tumor shrinkage) for patients treated with the Zybrestat/Avastin combination was no different, statistically, from patients treated with Avastin alone. An analysis of overall survival in the study is not ready. 

The overall survival data from this study is very important because convincing FDA to approve a drug for ovarian cancer that doesn't help patients live longer is a real challenge. Roche's Avastin is not approved for ovarian cancer in the U.S. despite a positive study reported in 2011 demonstrating a 52% reduction in the risk of tumor regrowth or death with a combination of Avastin plus chemotherapy compared to chemotherapy alone. The study -- dubbed AURELIA -- demonstrated overall survival favored Avastin but the trend was not statistically significant.  European regulators found the AURELIA study convincing enough for approval but Roche has so far not submitted the data to the FDA. (A Roche spokesman said an FDA submission is planned for later this year.)

Last June, Amgen (AMGN) reported results from a phase III study in which the combination of trebananib and chemotherapy reduced the risk of tumor re-growth or death (PFS) by 34% compared to chemotherapy alone. This study is also still being followed for overall survival. 

Both the Roche and Amgen studies are much larger than the Zybrestat study conducted by GOG, so Oxigene would likely need to conduct a larger, phase III study as well to confirm the findings announced Tuesday. 

Oxigene has previously studied Zybrestat in thyroid cancer and non-small cell lung cancer. 

Zybrestat belongs to a class of cancer drugs known as vascular disrupting agents (VDAs) that are designed to target and destroy blood vessels within tumors, thereby depriving them of oxygen and nutrients. VDAs are supposed to work against existing or more mature tumor blood vessels, compared to anti-angiogenesis inhibitors like Roche's Avastin, which work by preventing tumors from developing new blood vessels.



Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs